Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL) filed this Current Report on Form 8-K on May 27, 2026. The filing discloses new clinical and biopsy data from the Phase 1 ELIMINATE-B trial for its chronic hepatitis B candidate, PBGENE-HBV, presented at the European Association for the Study of the Liver (EASL) Congress 2026.
Key Financial Metrics
This filing is a non-financial disclosure regarding clinical trial progress. The document does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. Investors should refer to the Company's most recent Form 10-K or 10-Q for financial data.
Material Changes and Clinical Highlights
- cccDNA Elimination: New biopsy data indicate PBGENE-HBV directly eliminated cccDNA, resulting in a 1-log (10-fold) reduction in cccDNA-derived transcripts.
- Viral Inactivation: In the remaining <1% of cccDNA, the therapy permanently inactivated viral replication by knocking out polymerase function via indels.
- Biomarker Validation: pgRNA was established as a biomarker directly reflecting cccDNA elimination. 100% of patients (n=6) with detectable baseline pgRNA achieved complete loss of detectable blood pgRNA, correlating with undetectable pgRNA in liver biopsies.
- Safety Profile: As of the data cutoff, 38 doses were administered to 16 patients across 5 cohorts. No dose-limiting toxicities were observed. Common adverse events included transient infusion-related reactions.
- Adverse Events: Transient Grade 3 reversible ALT/AST abnormalities were observed without elevated bilirubin or Hy's law. Grade 3 hypotension occurred during dose escalation; one patient in the 0.8 mg/kg cohort experienced two serious adverse events (SAEs), one deemed treatment-related. The patient is stable.
Outlook, Risks, and Mitigation
The Company reports a clear therapeutic window and a manageable safety profile. Following the observation of hypotension, mitigation protocols (slower infusion rates and increased steroid doses) were implemented. Since implementation, up to 20% of doses have been administered under this protocol with no subsequent Grade 3 hypotension or Grade 3 LNP-related ALT/AST abnormalities. The filing includes standard forward-looking statement disclaimers regarding future clinical results and therapeutic windows.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed statistical data on the ELIMINATE-B trial.
- Review the Company's Form 10-K (fiscal year ended Dec 31, 2025) and Form 10-Q (quarter ended March 31, 2026) for financial liquidity and risk factors.
- Monitor future filings for updates on the implementation of the hypotension mitigation protocol and long-term safety data.
- Confirm the timeline for the next Phase 1 or Phase 2 trial milestones as discussed in the investor webcast.